Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Peking University People's Hospital116 enrolled

Overview

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast \>5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source. the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Study Type

OBSERVATIONAL

Enrollment

116

Conditions

Advanced MDS Without Identical Sibling Donor

Interventions

transplant with haploidentical donorPROCEDURE

patients with advanced MDS without identical sibling donor receive haploidentical transplant

Eligibility

Sex: ALLMin age: 2 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression * without identical sibling donor Exclusion Criteria: * Contraindication to HSCT * Pregnancy * Mental illness

Locations (8)

Nanfang Hospital, Nanfang Medical University

Guangzhou, Guangdong, China

Hebei Tangshan Steel and Iron Company Hospital

Tangshan, Hebei, China

Nanjing Gulou Hospital

Nanjing, Jiangsu, China

Suzhou University The 1st Affiliated Hospital

Suzhou, Jiangsu, China

Outcomes

Primary Outcomes

survival rate

number of participants with survival at one year

Time frame: participants will be followed for an expected average of one year

Secondary Outcomes

incidence of non-relapse mortality

number of participants with non-relapse mortality at one year

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.